Gene Therapy in Limelight on Novartis Deal: 3 Stocks in Focus – Zacks.com
SMA News Today |
Gene Therapy in Limelight on Novartis Deal: 3 Stocks in Focus
Zacks.com Per the agreement, Novartis will pay $8.7 billion for the buyout of this clinical stage gene therapy company. AveXis lead product candidate, AVXS-101, is being evaluated as one-time gene replacement therapy for spinal muscular atrophy, a disease which … Novartis to expand gene therapy pipeline with acquisition of AveXis for $8.7 billion Researchers Discover Promising New Gene Therapy Approach for Spinal Muscular Atrophy Medical breakthrough: Man is first adult to get new gene therapy for vision |
